Another BioCryst Factor D inhibitor hits clinical delay two months after first one discontinued
BioCryst’s most advanced experimental drug in its current pipeline has hit a snag, the company said Tuesday as part of its Q4 report.
BCX10013, an oral Factor D inhibitor for the treatment of complement-mediated diseases, is facing delays in a clinical program because of “recent dose-related observations” in a nonclinical study, according to BioCryst. The company didn’t say much more than that.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.